相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer
Stefano Fanti et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2021)
Apalutamide and Overall Survival in Prostate Cancer
Matthew R. Smith et al.
EUROPEAN UROLOGY (2021)
A Review of the Pathophysiological Mechanisms Underlying Castration-resistant Prostate Cancer
Fionnuala Crowley et al.
RESEARCH AND REPORTS IN UROLOGY (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
An FDA pooled analysis: Characteristics and outcomes of patients with nonmetastatic castration-resistant prostate cancer, based on prior history of prostatectomy and/or radiation therapy.
Jaleh Fallah et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Prostate Cancer, Version 1.2021 Featured Updates to the NCCN Guidelines
Edward Schaeffer et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)
Prevalence of potential drug-drug interactions among nonmetastatic castration-resistant prostate cancer patients treated with apalutamide and enzalutamide.
Sreevalsa Appukkuttan et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis
Marlon Perera et al.
EUROPEAN UROLOGY (2020)
The effect of androgen deprivation therapy on 68Ga-PSMA tracer uptake in non-metastatic prostate cancer patients
Cem Onal et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2020)
Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019
Silke Gillessena et al.
EUROPEAN UROLOGY (2020)
Optimum Imaging Strategies for Advanced Prostate Cancer: ASCO Guideline
Edouard J. Trabulsi et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Adverse event profiles of apalutamide, enzalutamide, and darolutamide in SPARTAN, PROSPER, and ARAMIS: How confident are we about which drug is safest?
Joshua Z. Drago et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
PSMA PET-CT redefines nonmetastatic castration-resistant prostate cancer
Piet Ost
NATURE REVIEWS UROLOGY (2020)
68Ga-PSMA-11 PET/CT in restaging castration-resistant nonmetastatic prostate cancer: detection rate, impact on patients' disease management and adequacy of impact
Aloyse Fourquet et al.
SCIENTIFIC REPORTS (2020)
Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer
Cora N. Sternberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Non-metastatic castration-resistant prostate cancer: current status and future directions
Ruby Gupta et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2020)
Comparative efficacy of apalutamide darolutamide and enzalutamide for treatment of non-metastatic castrate-resistant prostate cancer: A systematic review and network meta-analysis
Jatinder Kumar et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2020)
Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Keiichiro Mori et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2020)
Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide
Karim Fizazi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Managing Nonmetastatic Castration-resistant Prostate Cancer
Joaquin Mateo et al.
EUROPEAN UROLOGY (2019)
The Combination of Enzalutamide and Opioids: A Painful Pitfall?
Guillemette E. Benoist et al.
EUROPEAN UROLOGY (2019)
Drug-drug interaction (DDI) of darolutamide with cytochrome P450 (CYP) and P-glycoprotein (P-gp) substrates: Results from clinical and in vitro studies.
Christian Zurth et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer
Karim Fizazi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
A Rich Array of Prostate Cancer Molecular Biomarkers: Opportunities and Challenges
Indu Kohaar et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer
Wolfgang P. Fendler et al.
CLINICAL CANCER RESEARCH (2019)
Drug-Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies
Christian Zurth et al.
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS (2019)
Evaluation of Clinically Relevant Drug-Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial
Neal Shore et al.
TARGETED ONCOLOGY (2019)
Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer
Meghan A. Rice et al.
FRONTIERS IN ONCOLOGY (2019)
Efficacy, Predictive Factors, and Prediction Nomograms for Ga-68-labeled Prostate-specific Membrane Antigen-ligand Positron-emission Tomography/Computed Tomography in Early Biochemical Recurrent Prostate Cancer After Radical Prostatectomy
Isabel Rauscher et al.
EUROPEAN UROLOGY (2018)
Metastasis-free Survival - A New End Point in Prostate Cancer Trials
Julia A. Beaver et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer
Maha Hussain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
Matthew R. Smith et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Seizure Rates in Enzalutamide-Treated Men With Metastatic Castration-Resistant Prostate Cancer and Risk of Seizure The UPWARD Study
Susan Slovin et al.
JAMA ONCOLOGY (2018)
Metastasis-free Survival-Progress or Lowering the Bar on Nonmetastatic Prostate Cancer?
Leonardo O. Reis
EUROPEAN UROLOGY (2018)
Accuracy of 68Ga-PSMA11 PET/CT on recurrent prostate cancer: Preliminary results from a phase 2/3 prospective trial.
Wolfgang Fendler et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Recent Advances in Liquid Biopsy in Patients With Castration Resistant Prostate Cancer
Vincenzo Di Nunno et al.
FRONTIERS IN ONCOLOGY (2018)
Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Chemotherapy-naive and CYP17 Inhibitor-naive Patients: Follow-up from the ARADES and ARAFOR Trials
Neal D. Shore et al.
EUROPEAN UROLOGY FOCUS (2018)
Drug-drug interaction potential in men treated with enzalutamide: Mind the gap
Guillemette Emma Benoist et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer
Wanling Xie et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy
Shuang G. Zhao et al.
JAMA ONCOLOGY (2017)
Thresholds for PSA doubling time in men with non-metastatic castration-resistant prostate cancer
Lauren E. Howard et al.
BJU INTERNATIONAL (2017)
Enzalutamide and sleep apnea: an emerging central nervous system side-effect?
F. Labrize et al.
ANNALS OF ONCOLOGY (2016)
Skeletal complications in cancer patients with bone metastases
Shunsuke Tsuzuki et al.
INTERNATIONAL JOURNAL OF UROLOGY (2016)
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
Howard I. Scher et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Predictors of Time to Metastasis in Castration-resistant Prostate Cancer
Daniel M. Moreira et al.
UROLOGY (2016)
Efficacy of Immediate Switching from Bicalutamide to Flutamide as Second-Line Combined Androgen Blockade
Yumiko Yokomizo et al.
BIOMED RESEARCH INTERNATIONAL (2016)
Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy Effects of Androgen-Deprivation Therapy
Maxine Sun et al.
JAMA ONCOLOGY (2016)
Targeting molecular resistance in castration-resistant prostate cancer
Thenappan Chandrasekar et al.
BMC MEDICINE (2015)
The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995-2010
Bruce Guthrie et al.
BMC MEDICINE (2015)
Long-term Safety and Antitumor Activity in the Phase 1-2 Study of Enzalutamide in Pre- and Post-docetaxel Castration-Resistant Prostate Cancer
Celestia S. Higano et al.
EUROPEAN UROLOGY (2015)
Understanding the Mechanisms of Androgen Deprivation Resistance in Prostate Cancer at the Molecular Level
Theodoros Karantanos et al.
EUROPEAN UROLOGY (2015)
Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy
Matthias Eiber et al.
JOURNAL OF NUCLEAR MEDICINE (2015)
Prospective Comparison of F-18-Fluoromethylcholine Versus Ga-68-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy
Joshua J. Morigi et al.
JOURNAL OF NUCLEAR MEDICINE (2015)
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
Charles J. Ryan et al.
LANCET ONCOLOGY (2015)
The burden of skeletal-related events in patients with prostate cancer and bone metastasis
Florian Roghmann et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2015)
Burden of skeletal-related events in prostate cancer: unmet need in pain improvement
M. S. Broder et al.
SUPPORTIVE CARE IN CANCER (2015)
Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies
Anu-Maarit Moilanen et al.
SCIENTIFIC REPORTS (2015)
Comparison of choline-PET/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis
Guohua Shen et al.
SKELETAL RADIOLOGY (2014)
Elevated alkaline phosphatase velocity strongly predicts overall survival and the risk of bone metastases in castrate-resistant prostate cancer
Adam R. Metwalli et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2014)
Challenges and Recommendations for Early Identification of Metastatic Disease in Prostate Cancer
E. David Crawford et al.
UROLOGY (2014)
The Role of 11C-Choline and 18F-Fluorocholine Positron Emission Tomography (PET) and PET/CT in Prostate Cancer: A Systematic Review and Meta-analysis
Martin H. Umbehr et al.
EUROPEAN UROLOGY (2013)
Denosumab and Bone Metastasis-Free Survival in Men With Nonmetastatic Castration-Resistant Prostate Cancer: Exploratory Analyses by Baseline Prostate-Specific Antigen Doubling Time
Matthew R. Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Androgen receptors in hormone-dependent and castration-resistant prostate cancer
Ayesha A. Shafi et al.
PHARMACOLOGY & THERAPEUTICS (2013)
Whole-Body Diffusion-Weighted MRI Compared With 18F-NaF PET/CT for Detection of Bone Metastases in Patients With High-Risk Prostate Carcinoma
Firas Mosavi et al.
AMERICAN JOURNAL OF ROENTGENOLOGY (2012)
68Ga-Complex Lipophilicity and the Targeting Property of a Urea-Based PSMA Inhibitor for PET Imaging
Matthias Eder et al.
BIOCONJUGATE CHEMISTRY (2012)
ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
Nicola J. Clegg et al.
CANCER RESEARCH (2012)
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Howard I. Scher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
PSA velocity and doubling time in diagnosis and prognosis of prostate cancer
Andrew J. Vickers et al.
JOURNAL OF CLINICAL UROLOGY (2012)
Disease and Host Characteristics as Predictors of Time to First Bone Metastasis and Death in Men With Progressive Castration-Resistant Nonmetastatic Prostate Cancer
Matthew R. Smith et al.
CANCER (2011)
The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer:: a meta-analysis
A. M. Hovels et al.
CLINICAL RADIOLOGY (2008)
Implications of prostate-specific antigen doubling time as indicator of failure after surgery or radiation therapy for prostate cancer
Massimo Maffezzini et al.
EUROPEAN UROLOGY (2007)
Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer
MR Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
The natural history of prostate cancer
B Kessler et al.
UROLOGIC CLINICS OF NORTH AMERICA (2003)
分享论文
